Literature DB >> 11840345

Upregulation of DAF (CD55) on orbital fibroblasts by cytokines. Differential effects of TNF-beta and TNF-alpha.

E T Cocuzzi1, D S Bardenstein, A Stavitsky, N Sundarraj, M E Medof.   

Abstract

PURPOSE: Decay accelerating factor (DAF) and membrane cofactor protein (MCP) are membrane complement regulators that protect self cells from deposition of autologous C3b on their surfaces. CD59, a third downstream regulator of the cascade, prevents the assembly on self cells of autologous membrane-attack complexes. All three proteins are highly expressed on corneal and conjunctival epithelia, and are present in lower levels on multiple intraocular and adnexal cell types. The purpose of this study was to determine whether, and if so, how DAF, MCP and CD59 expression by ocular and adnexyl cells is modulated by cytokines.
METHODS: Primary cultures of orbital fibroblasts and corneal epithelial cells were incubated with TNF-alpha, TNF-beta, TGF-beta1, IFN-gamma, MIF or blocking anti-MIF mABs and extracts of the cells quantitated for DAF, MCP and CD59 by two-site immunoradiometric assays. Where inductions occurred, the kinetics of the increases, the effect of combining cytokines, and the effect of protein kinase-C inhibition were studied.
RESULTS: DAF expression on orbital fibroblasts was upregulated 6.3-, 3.7- and 4.2-fold by TGF-beta1, TNF-beta and IFN-gamma, respectively, but that its expression on corneal epithelial cells was minimally affected. These same (or other) cytokines did not significantly upregulate MCP or CD59. The cytokine-induced upregulation of DAF expression on orbital fibroblasts requires 24 hr for IFN-gamma or 48 hr for TGF-beta1 or TNF-beta, is dependent on new protein synthesis, and does not involve protein kinase-C activation.
CONCLUSIONS: TGF-beta1-, TNF-beta- and IFN-gamma-mediated upregulation of DAF should serve to prevent complement-mediated injury to orbital fibroblasts in the course of ocular inflammation. The induction by TNF-beta rather than TNF-alpha contrasts with that on all other cell types studied.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11840345     DOI: 10.1076/ceyr.23.2.86.5478

Source DB:  PubMed          Journal:  Curr Eye Res        ISSN: 0271-3683            Impact factor:   2.424


  9 in total

1.  Adenovirus type 11 uses CD46 as a cellular receptor.

Authors:  Anna Segerman; John P Atkinson; Marko Marttila; Veronica Dennerquist; Göran Wadell; Niklas Arnberg
Journal:  J Virol       Date:  2003-09       Impact factor: 5.103

2.  Levels of expression of complement regulatory proteins CD46, CD55 and CD59 on resting and activated human peripheral blood leucocytes.

Authors:  Stephen E Christmas; Claudia T de la Mata Espinosa; Deborah Halliday; Cheryl A Buxton; Joanne A Cummerson; Peter M Johnson
Journal:  Immunology       Date:  2006-09-26       Impact factor: 7.397

3.  Modulation of PBMC-decay accelerating factor (PBMC-DAF) and cytokines in rheumatoid arthritis.

Authors:  Roma Pahwa; Uma Kumar; Nibhriti Das
Journal:  Mol Cell Biochem       Date:  2016-02-23       Impact factor: 3.396

4.  Decay accelerating factor (CD55)-mediated attenuation of complement: therapeutic implications for age-related macular degeneration.

Authors:  Kelly N Ma; Siobhan M Cashman; J Harry Sweigard; Rajendra Kumar-Singh
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-08-04       Impact factor: 4.799

5.  Constitutive expression of murine decay-accelerating factor 1 is controlled by the transcription factor Sp1.

Authors:  David M Cauvi; Gabrielle Cauvi; K Michael Pollard
Journal:  J Immunol       Date:  2006-09-15       Impact factor: 5.422

6.  The African-387 C>T TGFB1 variant is functional and associates with the ophthalmoplegic complication in juvenile myasthenia gravis.

Authors:  Melissa Nel; Joy-Mari Buys; Robyn Rautenbach; Shaheen Mowla; Sharon Prince; Jeannine M Heckmann
Journal:  J Hum Genet       Date:  2015-12-03       Impact factor: 3.172

7.  Profiling of patient-specific myocytes identifies altered gene expression in the ophthalmoplegic subphenotype of myasthenia gravis.

Authors:  Melissa Nel; Sharon Prince; Jeannine M Heckmann
Journal:  Orphanet J Rare Dis       Date:  2019-01-29       Impact factor: 4.123

Review 8.  The role of decay accelerating factor in environmentally induced and idiopathic systemic autoimmune disease.

Authors:  Christopher B Toomey; David M Cauvi; Kenneth M Pollard
Journal:  Autoimmune Dis       Date:  2014-01-27

9.  A tandem repeat in decay accelerating factor 1 is associated with severity of murine mercury-induced autoimmunity.

Authors:  David M Cauvi; Rodney Gabriel; Dwight H Kono; Per Hultman; K Michael Pollard
Journal:  Autoimmune Dis       Date:  2014-04-10
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.